AVEO Pharmaceuticals — Investor Presentation (November 2016)
35 slides from AVEO Pharmaceuticals's investor presentation, Nov 8, 2016
Slide 1: AVEO Overview November 2016
AVEO Overview November 2016 Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward-looking statements. The words “anticipate,” “believe,” “estimate,”
Slide 3: Retained North American Rights for Oncology Portfolio While Leveraging Partnerships
Retained North American Rights for Oncology Portfolio While Leveraging Partnerships to Advance Our Pipeline AV-380 GDF15 MAb Tivozanib VEGFR 123 TKI (Oncology Indications) AV-203 ERBB3 MAb Ficlatuzumab HGF MAb Value Creation Strategy Leverage partner resources to advance development, retain signific
Slide 4: Multiple Opportunities for Value Creation
TIVO-1 (1st Line RCC) * Ocular SCCHN / AML (Investigator) Esophageal Cancer Cachexia TIVO-3 (U.S. Phase 3 Registration Study in RCC) TiNivo (+Opdivo® RCC) PAH Multiple Opportunities for Value Creation *Filed in EU by EUSA FEB 29, 2016, validated MAR 23, 2016 Seeking Partnership
Slide 5: Tivozanib
Tivozanib A potent, selective, long half-life inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2 and 3
Slide 6: Tivozanib: VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor
Tivozanib: VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor Potent, selective inhibitor of VEGFRs 1, 2 and 3 with a long half-life that is designed to optimize blockade while minimizing off-target toxicities1,2 1. Nakamura K et al. Cancer Res 2006;66:9134–9142. 2. Eskens FA et al. Clin Cancer Res 2011;17:
Slide 7: Large and Growing RCC Opportunity
MAA Review TIVO-3 : Tivo v. Sorafenib US Approval Decision EU Approval Decision NDA Review 2016 2017 2018 2019 2020 Ph 2 expansion or Ph 3 Trial of Tivo + PD-1 Potential NDA Filing 2H 2018 PFS Data/OS Trend Estimated 1Q 2018 Ph 1 Data 1H 2017 Large and Growing RCC Opportunity Market opportunity curr
Slide 8: Tivozanib RCC Front-line Setting
Tivozanib RCC Front-line Setting
Slide 9: TIVO-1: Proven Activity in 1st line RCC
Phase 3 TIVO-1: Proven Activity in 1st line RCC 517 patient, global, randomized Phase 3 in 1st line RCC First H2H RCC pivotal to meet primary PFS endpoint of superiority vs VEGF TKI OS confounded by crossover; NDA not approved; FDA requested additional study Demonstrated favorable tolerability profi
Slide 10: Comparable OS Despite Limited Subsequent Therapy
Comparable OS Despite Limited Subsequent Therapy
Slide 11: TIVO-1: Impact of Next-Line Therapy on OS
Support for Tivozanib MAA Filing for RCC TIVO-1: Impact of Next-Line Therapy on OS * EU includes Bulgaria, Czech Republic, France, UK, Hungary, Italy, Poland, Romania (countries with patients enrolled in Study 301) ** EU5 includes UK, Italy, and France (EU5 countries with patients enrolled in Study
Slide 12: EUSA Pharma Oncology Licensing Agreement
EUSA Pharma Oncology Licensing Agreement Specialty pharmaceutical company with commercial operations in the US and Europe, distribution network in 40 countries Spinout of Jazz Pharmaceuticals (Mar 2015) EU filing 2/29/16, validated 3/23/16, received 120 day questions July 2016 >$396M in Upfront and
Slide 13: Tivozanib is Well Tolerated, Potential Preferred TKI for PD-1 Combination
Tivozanib is Well Tolerated, and Has the Potential to Become the Preferred TKI for PD-1 Combination Therapy Single Agent Toxicity All grade (Gr 3/4) Sutent1 (n=548) Votrient1 (n=554) Inlyta5 (n=189) Nexavar3 (n=257) Lenvima4 (n=52) Cometriq2 (n=331) Tivozanib3 (n=259) Hypertension 30% (15%) 40% (4%)
Slide 14: Favorable Tolerability vs. Approved TKIs in RCC
Favorable Tolerability vs. Approved TKIs in RCC Incidence (%) Incidence (%) Tivozanib1 Sorafenib Pazopanib3 Axitinib2 TIVO-11 AXIS2 Sunitinib4 Dose Reductions Dose Interruptions Tivozanib1 Sorafenib Pazopanib3 Axitinib2 TIVO-11 AXIS2 Sunitinib4 Cabozantinib5 Lenvatinib+Everolimus6 Motzer et.al JCO 1
Slide 15: Top Three Toxicities Relevant to Patients with Advanced RCC
Top Three Toxicities Relevant to Patients with Advanced RCC* *Wong M, et al. J Med Econ. 2012;28:1-10. Additional months of PFS benefit patients require to accept adverse events >50% of pts on Nexavar <15% for Tivozanib >60% of pts on Sutent <20% for Tivozanib >50% of pts on Pazopanib, Axitinib and
Slide 16: Tivozanib Uniquely Positioned in 1st Line RCC
? 1 Motzer, et al. ESMO 2012 (COMPARZ): 1st line study, sutent vs. votrient 2 Hutson, et al. Lancet Oncol 2013 ; 14: 1245; 1L Phase 3 study vs sorafenib 3 Motzer, et al. JCO Oct 2013; 1st Line TIVO-1 Study, tivozanib vs. sorafenib 4 Choueri, et al. ESMO 2016. Poor and Intermediate risk patients only
Slide 17: Tivozanib North American Registration Strategy
Tivozanib North American Registration Strategy
Slide 18: TIVO-3: Phase 3 Study Design in Recurrent/Metastatic RCC
TIVO-3: Phase 3 Study Design in Recurrent/Metastatic RCC to Confirm TIVO-1 N = ~322 F Recurrent/metastatic RCC Failed at least two prior regimens including VEGFR-TKI (not sorafenib) ECOG PS 0 or 1 RANDOMIZE 1:1 tivozanib sorafenib 1O: PFS 2O: OS, ORR, DoR, Safety and tolerability for ITT & Pre-Speci
Slide 19: Tivozanib Efficacy in VEGF TKI Refractory Setting
Tivozanib Efficacy in VEGF TKI Refractory Setting * n= 389; investigator assessed PFS; independent PFS = 4.8 mo vs. 3.4 mo, HR = 0.741 (p=0.011) **investigator assessed PFS ^Cabozantanib USPI 1.Motzer et al Lancet Oncol 2013; 14: 552–62 2. Motzer et al Lancet Oncol 2014 3. Hutson et al ASCO 2015 4.
Slide 20: Tivozanib PD-1 Combination Setting
Tivozanib PD-1 Combination Setting
Slide 21: Rationale for Combining VEGF + PD-(L)1 Inhibitors
Rationale for Combining VEGF + PD-(L)1 Inhibitors Gunturi, McDermott Current Treatment Options in Oncology 2014 Plimack International Kidney Cancer Symposium 2014
Slide 22: Tivozanib Immunomodulatory Properties: Regulatory T Cell Reduction
Tivozanib has Immunomodulatory Properties: Regulatory T Cell Reduction May Enhance PD1 Activity Pawlowski N et al. AACR 2013. Poster 3971. Regulatory T cells suppress or downregulate induction and proliferation of effector T cells (e.g. CD4 and CD8) P=0.034
Slide 23: Early Data for the Combination of PD1 + VEGF TKIs
Early Data for the Combination of PD1 +VEGF TKIs: Demonstrated Promising Responses with Challenging Toxicity 1 Atkins et al, ESMO 2016, 2 Larkin et al, ESMO 2016 Phase Ib dose-finding studies of axitinib plus pembrolizumab or avelumab in treatment-naïve patients with advanced renal cell carcinoma Sa
Slide 24: Sunitinib & Pazopanib Have Overlapping Toxicities with PD1s
Sunitinib & Pazopanib, the most widely used VEGF TKIs, have potentially prohibitive overlapping toxicities with PD1s Courtesy of Dr. S. Pal, ASCO GU 2015
Slide 25: Significant TKI Dose Reductions Recommended to Combine with PD1s
Significant reductions of TKI dose to manage AEs have been recommended to safely combine some TKIs with PD1s in RCC CaboNivo1: Cabo recommended dose reduction from 60 to 40mg Lenvatinib + Pembro2: Lenv recommended dose reduction 24 to 20mg Reduced Dose May Adversely Impact Efficacy 1 Apolo et al, ES
Slide 26: Phase 1/2 TiNivo Study
Phase 1 TiNivo Study Tivozanib (1.0 mg/day) QD/21 days + nivolumab 240 mg Q 2 weeks N = 6 - 12 ECOG PS ≤ 1 and life expectancy ≥ 3 months Tivozanib (1.5 mg/day) QD/21 days + nivolumab 240 mg Q 2 weeks Further evaluate the antineoplastic activity and safety Phase 1 Phase 2 Maximum tolerated dose N =
Slide 27: High Potential Value Non-Oncology Programs
High Potential Value Non-Oncology Programs
Slide 28: Tivozanib in Ocular Diseases
Tivozanib in Ocular Diseases* >$105M total in upfront and potential option & milestone payments Potential for up to $10M in 2016/17 Tiered, double digit royalties, up to the mid-teens, on net sales** Option, milestone and royalty payments subject to the successful development and/or commercializatio
Slide 29: AV-380 in Cachexia
AV-380 in Cachexia Milestone and royalty payments subject to the successful development and/or commercialization of the product *A percentage of proceeds will be shared with SVH, including $1.5 million of upfront GDF-15 inhibitor Mab Indication: cachexia $327M in upfront & potential milestones Tiere
Slide 30: AV-353 in Pulmonary Arterial Hypertension
AV-353: 1st-in-class opportunity to address major unmet need in pulmonary arterial hypertension (PAH) as potential to be first drug with disease modifying properties Binding specificity to Notch 3 reduces risks of pan-Notch toxicities that have hampered competitors Large Market Opportunity 2014 sale
Slide 31: Financials & Summary
Financials & Summary
Slide 32: Financial Highlights
Financial Highlights Cash and anticipated operational milestones to fully fund North American tivozanib development strategy to topline data $30.8M in cash and investments as of 3Q 2016 Amended debt agreement provides potential access to another $5M tranche and deferred repayment of principal for ex
Slide 33: Potential Corporate Milestones
Potential Corporate Milestones 2016 2017 Regulatory decision in EU (1H17) Proof of concept in AMD and option exercise (2016/17) TIVO-3 PFS data/OS trend (1Q18) Other Potential Milestones Partnership for AV-353 Other tivozanib geographic partnerships Development milestones for AV-380 Manufacturing tr
Slide 34: AVEO Oncology Highlights
AVEO Oncology Highlights Retained significant North American rights for all oncology therapeutic assets Executing on development strategies for Tivozanib Enrolling Ph 3 refractory RCC study (TIVO-3) to support 1st & 3rd line indications Initiating Ph 1/2 tivozanib + Opdivo® combination study (TiNivo
Slide 35: AVEO Overview November 2016
AVEO Overview November 2016
AVEO Pharmaceuticals — Investor Presentation (November 2016) on 6ix